Business Description
ExpreS2ion Biotech Holding AB
ISIN : SE0023261292
Total Employee Number:
19Compare
Compare
Traded in other countries / regions
EXPRS2.Sweden5JD0.Germany IPO Date
2016-07-29Description
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 42.25 | |||||
Equity-to-Asset | 0.52 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -1.93 | |||||
Beneish M-Score | -15.51 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -37.8 | |||||
3-Year EBITDA Growth Rate | 51.5 | |||||
3-Year EPS without NRI Growth Rate | 52.4 | |||||
3-Year FCF Growth Rate | 48.4 | |||||
3-Year Book Growth Rate | -51.3 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 45.63 | |||||
9-Day RSI | 44 | |||||
14-Day RSI | 42.88 | |||||
3-1 Month Momentum % | -68.16 | |||||
6-1 Month Momentum % | -72.87 | |||||
12-1 Month Momentum % | -84.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.87 | |||||
Quick Ratio | 1.87 | |||||
Cash Ratio | 0.95 | |||||
Days Sales Outstanding | 169.6 | |||||
Days Payable | 227.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -44 | |||||
Shareholder Yield % | -0.02 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -19.15 | |||||
Operating Margin % | -1294.92 | |||||
Net Margin % | -1077.46 | |||||
EBITDA Margin % | -1245.58 | |||||
FCF Margin % | -1369.22 | |||||
OCF Margin % | -1369.22 | |||||
ROE % | -95.8 | |||||
ROA % | -54.68 | |||||
ROIC % | -111.72 | |||||
3-Year ROIIC % | 1146.66 | |||||
ROC (Joel Greenblatt) % | -6007.5 | |||||
ROCE % | -110.41 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 6.06 | |||||
PB Ratio | 0.55 | |||||
Price-to-Tangible-Book | 0.58 | |||||
EV-to-EBIT | 0.74 | |||||
EV-to-Forward-EBIT | 17.25 | |||||
EV-to-EBITDA | 0.76 | |||||
EV-to-Forward-EBITDA | 16.32 | |||||
EV-to-Revenue | -9.45 | |||||
EV-to-Forward-Revenue | 0.4 | |||||
EV-to-FCF | 0.69 | |||||
Price-to-GF-Value | 0.42 | |||||
Price-to-Median-PS-Value | 0.47 | |||||
| Price-to-Net-Current-Asset-Value | 0.76 | |||||
Earnings Yield (Greenblatt) % | 135.98 | |||||
FCF Yield % | -319.11 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ExpreS2ion Biotech Holding AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 3.363 | ||
| EPS (TTM) (kr) | -4.316 | ||
| Beta | 3.7952 | ||
| 3-Year Sharpe Ratio | -0.64 | ||
| 3-Year Sortino Ratio | -0.97 | ||
| Volatility % | 52.83 | ||
| 14-Day RSI | 42.88 | ||
| 14-Day ATR (kr) | 0.129702 | ||
| 20-Day SMA (kr) | 1.49525 | ||
| 12-1 Month Momentum % | -84.43 | ||
| 52-Week Range (kr) | 1.36 - 10.197844 | ||
| Shares Outstanding (Mil) | 9.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ExpreS2ion Biotech Holding AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ExpreS2ion Biotech Holding AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-12 | In 121 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 121 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-20 | In 37 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | In 37 days | ||
| General meeting for 2026 | 2026-06-25 10:00 | 1.52 (+2.36%) | ||
| Annual report for 2025 | 2026-06-04 | 1.61 (+0.63%) | ||
| First quarter earnings conference call for 2026 | 2026-05-28 10:00 | 1.66 (-10.27%) | ||
| First quarter earnings results for 2026 | 2026-05-28 | 1.66 (-10.27%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-19 09:30 | 5.54 (-1.15%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-19 | 5.54 (-1.15%) |
Show
Entries
ExpreS2ion Biotech Holding AB Frequently Asked Questions
What is ExpreS2ion Biotech Holding AB(OSTO:EXPRS2)'s stock price today?
The current price of OSTO:EXPRS2 is kr1.46. The 52 week high of OSTO:EXPRS2 is kr10.20 and 52 week low is kr1.36.
When is next earnings date of ExpreS2ion Biotech Holding AB(OSTO:EXPRS2)?
The next earnings date of ExpreS2ion Biotech Holding AB(OSTO:EXPRS2) is 2026-08-20.
Does ExpreS2ion Biotech Holding AB(OSTO:EXPRS2) pay dividends? If so, how much?
ExpreS2ion Biotech Holding AB(OSTO:EXPRS2) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on ExpreS2ion Biotech Holding AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers